Aptima® Mycoplasma genitalium Test
Mycoplasma genitalium (M. gen) is a highly prevalent STI
Testing for M. gen is recommended for all patients with recurrent urethritis, cervicitis and PID.1 Both women and men with M. gen infections are often asymptomatic and when left untreated, this infection can result in serious health consequences.1,2
Women
- Frequently asymptomatic1
- Detected in 10%-30% of women with clinical cervicitis1
- Prevalence of M. genitalium is identified in up to 22% of pelvic inflammatory disease (PID) cases1
- Untreated PID can lead to adverse pregnancy outcomes1
Men
- Responsible for 40% of persistent or recurrent urethritis in men1
Proper treatment depends on proper diagnosis
The treatment for each infection is organism-specific. An accurate diagnosis is critical to ensuring infections are treated successfully.3
Recommended treatments are organsim-specific
Chlamydia1
| Gonorrhea1
* For persons weighing ≥150 kg, 1 g Ceftriaxone should be administered. | Trichomoniasis1
|
Treatment considerations
M. GEN. 1A two-stage therapy approach accompanied with resistance testing, if available, is recommended for treating M. gen. 1
|
DNA-based tests can miss 40% of infections compared to rRNA-based tests.15
M. gen infection contains a very low organism load compared to other infections.14 Our RNA-based NAAT is far more sensitive than DNA-based tests—it accurately identified the 40% of patients with M. gen infections missed by DNA-based testing.15 The CDC recommends NAATs for detection of M. gen.1
Sensitivity of detection in patients with known M. genitalium infections:15,16
%
Aptima® M. genitalium assay RNA-based test
%
Aptima® M. genitalium assay RNA-based test
%
DNA-based LDT test
%
DNA-based test
*Sensitivity from Le Roy Study
†Sensitivity from Unemo Study. Performance in vaginal specimen.
†Sensitivity from Unemo Study. Performance in vaginal specimen.
Contact Us
We are here to support you. Have a question or need to talk to a Hologic team member?